CNN reports that an experimental treatment is showing promise for treating the genetic form of amyotrophic lateral sclerosis.
The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.
New Scientist reports that researchers have tested an ALS gene therapy in a mouse model of disease.
The assay was shown to have a simpler workflow and was able to detect mosaicism, with only a slight decrease in sensitivity compared to a lab-developed test.
The New York Genome Center created MetroNome as a way to show genomic data in the context of phenotypes, but integration challenges lie ahead.
Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Both a genome-wide association study and a rare variant burden analysis homed in on a role for KIF5A mutations in amyotrophic lateral sclerosis.
Gizmodo wonders whether CRISPR could present a treatment for amyotrophic lateral sclerosis.
Holden Thorp is to be the new editor-in-chief of Science and its related journals.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.
In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.